Flibanserin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

氟班色林是一种血清素能抗抑郁药，用于治疗性欲减退症。

Flibanserin is a full agonist of the 5-HT1A receptor (Ki = 1 nM) and, with lower affinity, as an antagonist of the 5-HT2A receptor (Ki = 49 nM) and antagonist or very weak partial agonist of the D4 receptor (Ki = 4–24 nM). Despite the much greater affinity of flibanserin for the 5-HT1A receptor, and for reasons that are unknown, flibanserin occupies the 5-HT1A and 5-HT2A receptors in vivo with similar percentages. Flibanserin also has low affinity for the 5-HT2B receptor (Ki = 89.3 nM) and the 5-HT2C receptor (Ki = 88.3 nM), both of which it behaves as an antagonist of. Flibanserin preferentially activates 5-HT1A receptors in the prefrontal cortex, demonstrating regional selectivity, and has been found to increase dopamine and norepinephrine levels and decrease serotonin levels in the rat prefrontal cortex, actions that were determined to be mediated by activation of the 5-HT1A receptor.[12] As such, flibanserin has been described as a norepinephrine-dopamine disinhibitor (NDDI). Flibanserin was approved in August 2015 for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD).(In Vitro):Flibanserin (0.01-100 μM; 72 h) can transform into two degradation products DP1 and DP2 with no toxicity potential after oxidative degradation.(In Vivo):Flibanserin (1, 10, 30 mg/kg; i.p.; single dose) shows different pharmacological properties in prefrontal cortex, hippocampus and midbrain. The 5-HT1A receptor occupancy in cortex indicates it’s the more sensitive than other brain region.Flibanserin (15, 45 mg/kg; p.o.; twice a day; 22 d) preferentially activates the brain regions belonging to the mesolimbic dopaminergic pathway and hypothalamic structures involved in the integration of sexual cues related to sexual motivation.Flibanserin (5, 10, 25, and 50 mg/kg; s.c.; single dose) has anxiolytic effects without locomotor side effects in rat ultrasonic vocalization model.

Flibanserin (0.01-100 μM; 72 h) can transform into two degradation products DP1 and DP2 with no toxicity potential after oxidative degradation.Cell Viability Assay Cell Line:NHSF cell lin Concentration:0.01, 0.1, 1, 10, 100 μM Incubation Time:72 hours Result:Resulted cell viability reached to 97.91% (DP1) and 96.73% (DP2) at 0.01 μM.

Flibanserin (1, 10, 30 mg/kg; i.p.; single dose) shows different pharmacological properties in prefrontal cortex, hippocampus and midbrain. The 5-HT1A receptor occupancy in cortex indicates it’s the more sensitive than other brain region.Flibanserin (15, 45 mg/kg; p.o.; twice a day; 22 d) preferentially activates the brain regions belonging to the mesolimbic dopaminergic pathway and hypothalamic structures involved in the integration of sexual cues related to sexual motivation.Flibanserin (5, 10, 25, and 50 mg/kg; s.c.; single dose) has anxiolytic effects without locomotor side effects in rat ultrasonic vocalization model. Animal Model:Long Evans female rats (225-250 g)Dosage:15 mg/kg; 45 mg/kg Administration:Oral gavage; twice a day for 22 daysResult:Increased the density of activated catecholaminergic neurons in the ventral tegmental area but not in the locus coeruleus.Increased Fos expression in the medial preoptic area and arcuate nucleus of the hypothalamus, ventral tegmental area, locus coeruleus, and lateral paragigantocellular nucleus with chronic 22-day treatment.Animal Model:Rat pup ultrasonic vocalization model of anxietyDosage:5, 10, 25, and 50 mg/kg Administration:Subcutaneous injection Result:Reduced ultrasonic vocalizations in rat pups.Showed effective within 30 min and has no severe locomotor side effects at active doses.

EBD6396 | Flibanserin. Brand name: Addyi

Others

Other Targets

5-HT1A|5-HT2A

Neurological Disease

——

167933-07-5

390.41

C20H21F3N4O

>98% (HPLC)

DMSO : ≥ 45 mg/mL; 115.27 mM

FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1

1-(2-{4-[3-(Trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2H-benzimidazol-2-one

(-20℃)

With Ice Pack

≥ 2 years